InvestorsObserver
×
News Home

Where Will Viking Therapeutics Inc (VKTX) Stock Go Next After It Is Higher By 8.71% in a Week?

Thursday, February 16, 2023 03:01 PM | InvestorsObserver Analysts

Mentioned in this article

Where Will Viking Therapeutics Inc (VKTX) Stock Go Next After It Is Higher By 8.71% in a Week?

Overall market sentiment has been high on Viking Therapeutics Inc (VKTX) stock lately. VKTX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Viking Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VKTX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With VKTX Stock Today?

Viking Therapeutics Inc (VKTX) stock is higher by 4.22% while the S&P 500 is down -0.37% as of 3:01 PM on Thursday, Feb 16. VKTX has gained $0.47 from the previous closing price of $11.14 on volume of 1,977,723 shares. Over the past year the S&P 500 is lower by -7.58% while VKTX has gained 207.14%. VKTX lost -$0.90 per share in the over the last 12 months.

More About Viking Therapeutics Inc

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Click Here to get the full Stock Report for Viking Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App